- Home
- BCTXW vs STKL Comparison
BCTXW vs STKL Comparison
Compare BCTXW & STKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTXW
- STKL
- Stock Information
- Founded
- BCTXW N/A
- STKL 1973
- Country
- BCTXW Canada
- STKL United States
- Employees
- BCTXW 12
- STKL N/A
- Industry
- BCTXW Biotechnology: Pharmaceutical Preparations
- STKL Precious Metals
- Sector
- BCTXW Health Care
- STKL Basic Materials
- Exchange
- BCTXW Nasdaq
- STKL Nasdaq
- Market Cap
- BCTXW N/A
- STKL N/A
- IPO Year
- BCTXW N/A
- STKL N/A
- Fundamental
- Price
- BCTXW $0.34
- STKL $7.76
- Analyst Decision
- BCTXW
- STKL Strong Buy
- Analyst Count
- BCTXW 0
- STKL 4
- Target Price
- BCTXW N/A
- STKL $9.50
- AVG Volume (30 Days)
- BCTXW N/A
- STKL 547.5K
- Earning Date
- BCTXW N/A
- STKL 11-05-2024
- Dividend Yield
- BCTXW N/A
- STKL N/A
- EPS Growth
- BCTXW N/A
- STKL N/A
- EPS
- BCTXW N/A
- STKL N/A
- Revenue
- BCTXW N/A
- STKL $711,683,000.00
- Revenue This Year
- BCTXW N/A
- STKL $15.65
- Revenue Next Year
- BCTXW N/A
- STKL $9.32
- P/E Ratio
- BCTXW N/A
- STKL N/A
- Revenue Growth
- BCTXW N/A
- STKL 16.96
- 52 Week Low
- BCTXW N/A
- STKL $4.78
- 52 Week High
- BCTXW N/A
- STKL $8.11
- Technical
- Relative Strength Index (RSI)
- BCTXW N/A
- STKL 61.45
- Support Level
- BCTXW N/A
- STKL $7.58
- Resistance Level
- BCTXW N/A
- STKL $8.00
- Average True Range (ATR)
- BCTXW 0.00
- STKL 0.24
- MACD
- BCTXW 0.00
- STKL -0.04
- Stochastic Oscillator
- BCTXW 0.00
- STKL 57.14
About BCTXW BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.